SCYNEXIS, Inc. (SCYX) financial statements (2022 and earlier)

Company profile

Business Address 1 EVERTRUST PLAZA
JERSEY CITY, NJ 07302-6548
State of Incorp.
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments104,48493,04148,41444,15743,89358,58646,985
Cash and cash equivalents104,48493,04141,92011,43911,46935,65646,985
Short-term investments  6,49432,71832,42422,930 
Restricted cash and investments   55   
Receivables861   251233430
Inventory, net of allowances, customer advances and progress billings463      
Inventory463      
Prepaid expense3,318381271220341314376
Deferred costs    314 417
Other current assets437367454914138
Other undisclosed current assets2474,4113,0436,97770153191
Total current assets:109,37798,20652,40251,46344,96059,32748,437
Noncurrent Assets
Operating lease, right-of-use asset2,8012,9993,191
Property, plant and equipment113298405516  42
Intangible assets, net (including goodwill)1,056      
Intangible assets, net (excluding goodwill)1,056      
Restricted cash and investments218273273273   
Deferred costs15018770106   
Other noncurrent assets6,122573812812576120419
Other undisclosed noncurrent assets    314345375
Total noncurrent assets:10,4604,3304,7511,707890465836
TOTAL ASSETS:119,837102,53657,15353,17045,85059,79249,273
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities13,5468,78010,9785,7565,5383,4603,768
Accounts payable7,8484,6397,1773,6533,8332,192619
Accrued liabilities5,6984,1413,8012,1031,7051,2683,149
Debt  36 4,349  
Deferred revenue and credits257257257
Other undisclosed current liabilities7017,616 121  2,639
Total current liabilities:13,61626,39611,0145,87710,1443,7176,664
Noncurrent Liabilities
Long-term debt and lease obligation31,9493,2743,32615,08210,30314,252 
Long-term debt, excluding current maturities28,745  15,08210,30314,252 
Operating lease, liability3,2043,2743,326
Liabilities, other than long-term debt3,345   121403660
Deferred revenue and credits121403660
Other liabilities3,345      
Other undisclosed noncurrent liabilities29,66946,83429,9189863,8726,601 
Total noncurrent liabilities:64,96353,38233,24416,06814,29621,256660
Total liabilities:78,57979,77844,25821,94524,44024,9737,324
Stockholders' equity
Stockholders' equity attributable to parent, including:41,25822,75812,89531,22521,41034,81941,949
Additional paid in capital400,705349,351284,226248,895226,631214,918192,069
Accumulated deficit(359,479)(326,613)(271,428)(217,718)(205,250)(180,123)(150,134)
Other undisclosed stockholders' equity attributable to parent32209748292414
Total stockholders' equity:41,25822,75812,89531,22521,41034,81941,949
TOTAL LIABILITIES AND EQUITY:119,837102,53657,15353,17045,85059,79249,273

Income statement (P&L) ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Revenues13,163 121257257257257
Revenue, net3002572,397
Gross profit:13,163 121257257257257
Operating expenses(74,001)(51,149)(49,042)(30,240)(26,577)(28,074)(28,606)
Operating loss:(60,838)(51,149)(48,921)(29,983)(26,320)(27,817)(28,349)
Nonoperating income (expense)24,884(7,184)(4,789)10,7791,260(2,172)11
Investment income, nonoperating1,1702,2571,567111(124)(315) 
Interest and debt expense(2,725)(1,766)(1,045)(1,626)(1,455)(351) 
Loss from continuing operations before equity method investments, income taxes:(38,679)(60,099)(54,755)(20,830)(26,515)(30,340)(28,338)
Other undisclosed income from continuing operations before income taxes2,7251,7661,0451,6261,415351 
Loss from continuing operations before income taxes:(35,954)(58,333)(53,710)(19,204)(25,100)(29,989)(28,338)
Income tax benefit3,0883,148 6,736   
Loss from continuing operations:(32,866)(55,185)(53,710)(12,468)(25,100)(29,989)(28,338)
Loss from discontinued operations      (4,285)
Net loss:(32,866)(55,185)(53,710)(12,468)(25,100)(29,989)(32,623)
Other undisclosed net income attributable to parent    40  
Net loss available to common stockholders, diluted:(32,866)(55,185)(53,710)(12,468)(25,060)(29,989)(32,623)

Comprehensive Income ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Net loss:(32,866)(55,185)(53,710)(12,468)(25,100)(29,989)(32,623)
Comprehensive loss, net of tax, attributable to parent:(32,866)(55,185)(53,710)(12,468)(25,100)(29,989)(32,623)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: